Managing Toxicity of Intravesical Therapy
| Autor: | Joachim Mathes, Tilman Todenhöfer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Bladder cancer Drug-Related Side Effects and Adverse Reactions business.industry Mitomycin Urology 030232 urology & nephrology Antineoplastic Agents Effective management medicine.disease Severity of Illness Index 03 medical and health sciences Administration Intravesical 0302 clinical medicine Adjuvants Immunologic Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Internal medicine Toxicity BCG Vaccine medicine Humans business Urothelial carcinoma |
| Zdroj: | European Urology Focus. 4:464-467 |
| ISSN: | 2405-4569 |
| DOI: | 10.1016/j.euf.2018.09.009 |
| Popis: | Intravesical therapies have shown positive effects both on recurrence and progression of non-muscle-invasive bladder cancer. However, more than 50% of patients experience untoward side effects associated with treatment. In order to reduce the rate of patients who discontinue treatment due to side effects, prevention and effective management of treatment-related toxicity is essential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect